Oncodea
- | Diagnostics
- | Medical device or technology
Oncodea aims to make early cancer detection more accurate, low-cost, and accessible to anyone who wants to screen for early signs of cancer. Our technology, OncodeAi™, is a cell-free cancer early detection (CED) platform that addresses early cancer screening gaps by leveraging nanoparticle-enhanced infrared (nano-IR) molecular sensing and advanced artificial intelligence (AI) techniques to detect cancer molecular fingerprints in serum from a small blood sample. The platform detects diverse biomolecular markers released by cancer and affected cells into the bloodstream, serving as universal molecular fingerprints. This innovative approach aims to improve early detection and offer a non-invasive, low-cost, and accurate alternative to existing screening methods, with the potential use of micro-blood samples for increased screening accessibility and compliance. The technology can be easily scaled up and expanded into other cancer types, including lung, colorectal, and prostate cancer.
Address
Saint PaulMinnesota
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}